Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:18
01/25/21
01/25
12:18
01/25/21
12:18
MRK

Merck

$80.68 /

-0.28 (-0.35%)

, GME

GameStop

$95.00 /

+30.27 (+46.76%)

, MRNA

Moderna

$142.70 /

+11.65 (+8.89%)

, PFE

Pfizer

$36.94 /

+0.395 (+1.08%)

, NCR

NCR Corp.

$33.98 /

+0.56 (+1.68%)

, CATM

Cardtronics

$38.50 /

-2.4 (-5.87%)

, APO

Apollo Global

$46.02 /

-0.445 (-0.96%)

, BBBY

Bed Bath & Beyond

$34.03 /

+3.8 (+12.57%)

, BB

BlackBerry

$18.62 /

+4.59 (+32.72%)

, SOL

ReneSola

$26.72 /

-6.92 (-20.57%)

, MGNI

Magnite

$36.91 /

-3.175 (-7.92%)

The major averages are…

ShowHide Related Items >><<
MRK Merck
$80.68 /

-0.28 (-0.35%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

01/21/21 Wedbush
Scholar Rock price target raised to $66 from $47 at Wedbush
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
01/06/21 Citi
Citi opens 'positive catalyst watch' on Merck
GME GameStop
$95.00 /

+30.27 (+46.76%)

09:52 Today
Fly Intel: Top five analyst downgrades
08:57 Today Telsey Advisory
GameStop continues surge despite double downgrade at Telsey Advisory
05:37 Today Telsey Advisory
GameStop downgraded to Underperform from Outperform at Telsey Advisory
01/13/21 Standpoint Research
GameStop downgraded to Hold from Buy at Standpoint Research
MRNA Moderna
$142.70 /

+11.65 (+8.89%)

09:47 Today Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
PFE Pfizer
$36.94 /

+0.395 (+1.08%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

01/11/21 Wells Fargo
Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39
01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
12/14/20 Craig-Hallum
Par Technology price target raised to $75 from $55 at Craig-Hallum
CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

11:00 Today Truist
Cardtronics downgraded to Hold from Buy at Truist
01/11/21 Wells Fargo
Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39
01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
APO Apollo Global
$46.02 /

-0.445 (-0.96%)

01/20/21 Truist
Athene Holding price target raised to $55 from $48 at Truist
01/11/21 Wells Fargo
Apollo Global price target raised to $55 from $50 at Wells Fargo
12/18/20 Deutsche Bank
Apollo Global price target raised to $51 from $49 at Deutsche Bank
11/06/20
Fly Intel: Top five analyst upgrades
BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

07:22 Today Loop Capital
Bed Bath & Beyond price target raised to $30 from $18 at Loop Capital
01/08/21 Wedbush
Bed Bath & Beyond Q3 results 'mixed,' says Wedbush
01/08/21 Baird
Bed Bath & Beyond elevated to Fresh Pick at Baird
01/05/21 Baird
Bed Bath & Beyond Q3 expectations remain low, says Baird
BB BlackBerry
$18.62 /

+4.59 (+32.72%)

12/18/20 TD Securities
BlackBerry price target raised to $8.50 from $5.50 at TD Securities
12/15/20 RBC Capital
BlackBerry price target raised to $7.50 from $5 at RBC Capital
12/15/20 RBC Capital
BlackBerry price target raised to $7.50 from $5.00 at RBC Capital
12/01/20 TD Securities
BlackBerry jump on AWS pact looks like overreaction, says TD Securities
SOL ReneSola
$26.72 /

-6.92 (-20.57%)

12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
12/14/20 H.C. Wainwright
ReneSola price target raised to $12 from $4 at H.C. Wainwright
09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
MGNI Magnite
$36.91 /

-3.175 (-7.92%)

01/24/21 Truist
Magnite downgraded to Hold from Buy at Truist
01/22/21 Craig-Hallum
Magnite price target raised to $45 from $25 at Craig-Hallum
01/11/21 Susquehanna
Magnite weakness a buying opportunity, says Susquehanna
12/21/20 Needham
Magnite price target raised to $30 from $18 at Needham
MRK Merck
$80.68 /

-0.28 (-0.35%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

  • 19
    May
  • 12
    Feb
MRK Merck
$80.68 /

-0.28 (-0.35%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

NCR NCR Corp.
$33.98 /

+0.56 (+1.68%)

CATM Cardtronics
$38.50 /

-2.4 (-5.87%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

MRK Merck
$80.68 /

-0.28 (-0.35%)

GME GameStop
$95.00 /

+30.27 (+46.76%)

MRNA Moderna
$142.70 /

+11.65 (+8.89%)

PFE Pfizer
$36.94 /

+0.395 (+1.08%)

APO Apollo Global
$46.02 /

-0.445 (-0.96%)

BBBY Bed Bath & Beyond
$34.03 /

+3.8 (+12.57%)

BB BlackBerry
$18.62 /

+4.59 (+32.72%)

SOL ReneSola
$26.72 /

-6.92 (-20.57%)

MGNI Magnite
$36.91 /

-3.175 (-7.92%)

Conference/Events
Sunnova Energy management to meet virtually with KeyBanc » 11:12
01/25/21
01/25
11:12
01/25/21
11:12
NOVA

Sunnova Energy

$52.50 /

-1.35 (-2.51%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NOVA Sunnova Energy
$52.50 /

-1.35 (-2.51%)

NOVA Sunnova Energy
$52.50 /

-1.35 (-2.51%)

01/20/21 JPMorgan
Sunnova Energy price target raised to $58 from $49 at JPMorgan
01/20/21 Credit Suisse
Sunnova Energy price target raised to $48 from $40 at Credit Suisse
01/19/21 Piper Sandler
Sunnova Energy price target raised to $55 from $35 at Piper Sandler
01/04/21 Goldman Sachs
Sunnova Energy price target raised to $60 from $45 at Goldman Sachs
NOVA Sunnova Energy
$52.50 /

-1.35 (-2.51%)

  • 16
    Dec
  • 01
    Dec
  • 14
    Aug
  • 01
    Jul
NOVA Sunnova Energy
$52.50 /

-1.35 (-2.51%)

NOVA Sunnova Energy
$52.50 /

-1.35 (-2.51%)

On The Fly
Walmart downgrade, Alibaba initiation among today's top calls on Wall Street » 10:07
01/25/21
01/25
10:07
01/25/21
10:07
WMT

Walmart

$144.48 /

-1.96 (-1.34%)

, BABA

Alibaba

$263.42 /

+4.775 (+1.85%)

, JD

JD.com

$99.50 /

+4.59 (+4.84%)

, PDD

Pinduoduo

$190.93 /

+18.96 (+11.03%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MPNGF

Meituan

$0.00 /

+ (+0.00%)

, BILI

Bilibili

$138.37 /

+4.61 (+3.45%)

, TSLA

Tesla

$879.53 /

+32.29 (+3.81%)

, WFC

Wells Fargo

$31.71 /

-0.18 (-0.56%)

, GME

GameStop

$90.50 /

+25.77 (+39.81%)

Check out today's top…

ShowHide Related Items >><<
WMT Walmart
$144.48 /

-1.96 (-1.34%)

WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

TSLA Tesla
$879.53 /

+32.29 (+3.81%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

JD JD.com
$99.50 /

+4.59 (+4.84%)

GME GameStop
$90.50 /

+25.77 (+39.81%)

BILI Bilibili
$138.37 /

+4.61 (+3.45%)

BABA Alibaba
$263.42 /

+4.775 (+1.85%)

WMT Walmart
$144.48 /

-1.96 (-1.34%)

09:52 Today
Fly Intel: Top five analyst downgrades
08:34 Today R5 Capital
R5 Capital downgrades 'operationally challenged' Walmart to Sell
07:14 Today R5 Capital
Walmart downgraded to Sell from Hold at R5 Capital
01/22/21 Jefferies
Walmart has upside potential to $200 per share, says Jefferies
BABA Alibaba
$263.42 /

+4.775 (+1.85%)

09:52 Today
Fly Intel: Top five analyst initiations
06:17 Today Bernstein
Alibaba initiated with a Market Perform at Bernstein
01/22/21 Truist
Alibaba price target raised to $326 from $308 at Truist
01/13/21 Mizuho
Alibaba price target lowered to $270 from $300 at Mizuho
JD JD.com
$99.50 /

+4.59 (+4.84%)

06:15 Today Bernstein
JD.com initiated with an Outperform at Bernstein
01/14/21 Jefferies
JD Health initiated with a Buy at Jefferies
01/08/21 Mizuho
JD.com price target raised to $105 from $90 at Mizuho
PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

06:15 Today Bernstein
Pinduoduo initiated with an Outperform at Bernstein
12/28/20 UBS
Pinduoduo, JD could benefit if Alibaba forced to be less aggressive, says UBS
12/10/20 Oppenheimer
Boqii initiated with a Perform at Oppenheimer
11/19/20 Barclays
Pinduoduo price target raised to $125 from $79 at Barclays
TCEHY Tencent
$0.00 /

+ (+0.00%)

06:13 Today Bernstein
Tencent initiated with an Outperform at Bernstein
01/22/21 Investec
Tencent downgraded to Sell from Hold at Investec
01/05/21 New Street
Tencent named a top idea for 2021 at New Street
01/05/21 Jefferies
Yeahka initiated with a Buy at Jefferies
MPNGF Meituan
$0.00 /

+ (+0.00%)

06:14 Today Bernstein
Meituan initiated with an Outperform at Bernstein
11/09/20 KeyBanc
Meituan initiated with a Sector Weight at KeyBanc
07/21/20 JPMorgan
Meituan Dianping downgraded to Neutral from Overweight at JPMorgan
BILI Bilibili
$138.37 /

+4.61 (+3.45%)

06:16 Today Bernstein
Bilibili initiated with an Outperform at Bernstein
12/16/20 Morgan Stanley
Bilibili named Research Tactical Idea at Morgan Stanley
11/19/20 Daiwa
Bilibili upgraded to Buy from Outperform at Daiwa
11/19/20 Citi
Bilibili price target raised to $60 from $58 at Citi
TSLA Tesla
$879.53 /

+32.29 (+3.81%)

08:44 Today Morgan Stanley
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
08:16 Today Baird
Baird ups Tesla target, says Musk may want 'superstructure' of businesses
01/22/21 JPMorgan
JPMorgan boosts target on 'lofty' valued Tesla to $125 from $105
01/22/21 Nomura
Nomura starts 'Tesla-like' NIO with Buy rating, $80.30 price target
WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

09:52 Today
Fly Intel: Top five analyst upgrades
06:02 Today Credit Suisse
Wells Fargo upgraded to Outperform from Neutral at Credit Suisse
01/19/21 DA Davidson
Wells Fargo price target raised to $39 from $36 at DA Davidson
01/19/21 Seaport Global
Wells Fargo upgraded to Buy from Neutral at Seaport Global
GME GameStop
$90.50 /

+25.77 (+39.81%)

08:57 Today Telsey Advisory
GameStop continues surge despite double downgrade at Telsey Advisory
05:37 Today Telsey Advisory
GameStop downgraded to Underperform from Outperform at Telsey Advisory
01/13/21 Standpoint Research
GameStop downgraded to Hold from Buy at Standpoint Research
WMT Walmart
$144.48 /

-1.96 (-1.34%)

WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

TSLA Tesla
$879.53 /

+32.29 (+3.81%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

JD JD.com
$99.50 /

+4.59 (+4.84%)

GME GameStop
$90.50 /

+25.77 (+39.81%)

BILI Bilibili
$138.37 /

+4.61 (+3.45%)

BABA Alibaba
$263.42 /

+4.775 (+1.85%)

  • 18
    Nov
  • 14
    Feb
WMT Walmart
$144.48 /

-1.96 (-1.34%)

WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

TSLA Tesla
$879.53 /

+32.29 (+3.81%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

JD JD.com
$99.50 /

+4.59 (+4.84%)

GME GameStop
$90.50 /

+25.77 (+39.81%)

BILI Bilibili
$138.37 /

+4.61 (+3.45%)

BABA Alibaba
$263.42 /

+4.775 (+1.85%)

WMT Walmart
$144.48 /

-1.96 (-1.34%)

WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

TSLA Tesla
$879.53 /

+32.29 (+3.81%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

JD JD.com
$99.50 /

+4.59 (+4.84%)

GME GameStop
$90.50 /

+25.77 (+39.81%)

BILI Bilibili
$138.37 /

+4.61 (+3.45%)

BABA Alibaba
$263.42 /

+4.775 (+1.85%)

WMT Walmart
$144.48 /

-1.96 (-1.34%)

WFC Wells Fargo
$31.71 /

-0.18 (-0.56%)

TSLA Tesla
$879.53 /

+32.29 (+3.81%)

PDD Pinduoduo
$190.93 /

+18.96 (+11.03%)

JD JD.com
$99.50 /

+4.59 (+4.84%)

GME GameStop
$90.50 /

+25.77 (+39.81%)

BILI Bilibili
$138.37 /

+4.61 (+3.45%)

BABA Alibaba
$263.42 /

+4.775 (+1.85%)

Options
Moderna call volume above normal and directionally bullish » 10:05
01/25/21
01/25
10:05
01/25/21
10:05
MRNA

Moderna

$145.00 /

+13.95 (+10.64%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

09:47 Today Piper Sandler
Piper reiterates $170 target on Moderna with vaccine active on new strains
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

MRNA Moderna
$145.00 /

+13.95 (+10.64%)

Recommendations
Piper reiterates $170 target on Moderna with vaccine active on new strains » 09:47
01/25/21
01/25
09:47
01/25/21
09:47
MRNA

Moderna

$141.57 /

+10.52 (+8.03%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $170 price target after the company announced that mRNA-1273 retained activity and produced neutralizing titers against emerging SARS-CoV-2 variants including the U.K. strain B.1.1.7 and South Africa strain B.1.351. No significant impact on neutralizing titers against the B.1.1.7 variant was observed, although a six-fold reduction in neutralizing titers was observed with the B.1.351 variant versus. prior strains, Tenthoff tells investors in a research note. Despite the slow vaccination pace, Moderna expects to deliver 200M mRNA-1273 doses in the U.S. by end of Q2, and 600M to to 1B doses globally by the end of 2021, the analyst points out. He thinks the SARS-CoV-2 booster vaccine will be able to further boost any of the leading vaccine candidates, which "could provide a revenue tail" for mRNA-1273.

ShowHide Related Items >><<
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

MRNA Moderna
$141.57 /

+10.52 (+8.03%)

Recommendations
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value » 08:44
01/25/21
01/25
08:44
01/25/21
08:44
GOOGL

Alphabet Class A

$1,892.13 /

+9.73 (+0.52%)

, GOOG

Alphabet

$1,900.21 /

+10.36 (+0.55%)

, FB

Facebook

$274.63 /

+1.64 (+0.60%)

, AMZN

Amazon.com

$3,290.00 /

-18.3 (-0.55%)

, AAPL

Apple

$138.93 /

+2.04 (+1.49%)

, MSFT

Microsoft

$225.82 /

+0.93 (+0.41%)

, TSLA

Tesla

$846.69 /

+1.86 (+0.22%)

Morgan Stanley analyst…

Morgan Stanley analyst Brian Nowak argues that Alphabet (GOOGL) and Facebook (FB) are the only two "mega-cap" tech companies not trading on some version of a sum-of-the-the parts valuation methodology with Amazon (AMZN), Microsoft (MSFT), Apple (AAPL) and Tesla (TSLA) "all having moved in this direction." However, he also believes the market is getting closer to the "appreciating and realizing" this value at Alphabet and thinks that continued YouTube revenue disclosure and upcoming full Google Cloud segment disclosure should help investors better understand and value Alphabet's underlying drivers. The analyst, who said his updated sum-of-the-parts analysis "speaks to how disclosure could drive Alphabet towards" being valued at $2,800 per share, keeps an Overweight rating and $2,050 price target on the stock.

ShowHide Related Items >><<
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

FB Facebook
$274.63 /

+1.64 (+0.60%)

AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

AAPL Apple
$138.93 /

+2.04 (+1.49%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

07:09 Today Mizuho
Alphabet price target raised to $2,100 from $1,810 at Mizuho
01/21/21
Fly Intel: Top five analyst initiations
01/20/21 Piper Sandler
Alphabet assumed with an Overweight at Piper Sandler
01/19/21 JPMorgan
JPMorgan says buy 'FANG' stocks amid 'fatigue and frustration'
GOOG Alphabet
$1,900.21 /

+10.36 (+0.55%)

08:15 Today Canaccord
Alphabet price target raised to $2250 from $2050 at Canaccord
FB Facebook
$274.63 /

+1.64 (+0.60%)

01/22/21 Truist
Facebook price target raised to $320 from $310 at Truist
01/22/21 Oppenheimer
Facebook price target raised to $345 from $300 at Oppenheimer
01/22/21 Credit Suisse
Facebook price target lowered to $325 from $330 at Credit Suisse
01/22/21 JPMorgan
Facebook shares 'compelling' into Q4 results, says JPMorgan
AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

07:22 Today Loop Capital
Bed Bath & Beyond price target raised to $30 from $18 at Loop Capital
01/22/21 Credit Suisse
Amazon.com price target raised to $3,860 from $3,750 at Credit Suisse
01/21/21 BofA
Amazon.com price target raised to $4,000 from $3,650 at BofA
AAPL Apple
$138.93 /

+2.04 (+1.49%)

08:27 Today Evercore ISI
Evercore ISI raises Apple price target to $160, sees higher odds of car product
07:33 Today Raymond James
Apple price target raised to $150 from $140 at Raymond James
07:19 Today JPMorgan
JPMorgan sees 'large beat' from Apple, keeps $150 price target
05:07 Today Raymond James
Apple price target raised to $150 from $140 at Raymond James
MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

08:00 Today DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
01/22/21 RBC Capital
Varonis price target raised to $200 from $165 at RBC Capital
01/21/21 Goldman Sachs
Microsoft initiated with a Buy at Goldman Sachs
01/21/21 Cleveland Research
Microsoft demand beat expectations in December quarter, says Cleveland Research
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

08:16 Today Baird
Baird ups Tesla target, says Musk may want 'superstructure' of businesses
01/22/21 JPMorgan
JPMorgan boosts target on 'lofty' valued Tesla to $125 from $105
01/22/21 Nomura
Nomura starts 'Tesla-like' NIO with Buy rating, $80.30 price target
01/20/21 JPMorgan
JPMorgan boosts GM target to $63, calls 'significant contender' in autonomous
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

GOOG Alphabet
$1,900.21 /

+10.36 (+0.55%)

FB Facebook
$274.63 /

+1.64 (+0.60%)

AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

AAPL Apple
$138.93 /

+2.04 (+1.49%)

  • 14
    Feb
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

FB Facebook
$274.63 /

+1.64 (+0.60%)

AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

AAPL Apple
$138.93 /

+2.04 (+1.49%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

FB Facebook
$274.63 /

+1.64 (+0.60%)

AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

AAPL Apple
$138.93 /

+2.04 (+1.49%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

MSFT Microsoft
$225.82 /

+0.93 (+0.41%)

GOOGL Alphabet Class A
$1,892.13 /

+9.73 (+0.52%)

GOOG Alphabet
$1,900.21 /

+10.36 (+0.55%)

FB Facebook
$274.63 /

+1.64 (+0.60%)

AMZN Amazon.com
$3,290.00 /

-18.3 (-0.55%)

AAPL Apple
$138.93 /

+2.04 (+1.49%)

Hot Stocks
Moderna announces results from COVID-19 Vaccine study against new strains » 08:32
01/25/21
01/25
08:32
01/25/21
08:32
MRNA

Moderna

$131.01 /

-1.97 (-1.48%)

Moderna announced results…

Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2. Vaccination with the Moderna COVID-19 Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective. This study was conducted in collaboration with the Vaccine Research Center, or VRC, at the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH. The manuscript has been submitted as a preprint to bioRxiv and will be submitted for peer-reviewed publication. The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 microgram dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the company will test an additional booster dose of its COVID-19 Vaccine to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the company is advancing an emerging variant booster candidate against the B.1.351 variant first identified in the Republic of South Africa. The company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the U.S. to evaluate the immunological benefit of boosting with strain-specific spike proteins. Moderna expects that its mRNA-based booster vaccine will be able to further boost neutralizing titers in combination with all of the leading vaccine candidates. First detected in September 2020 in the United Kingdom, the SARS-CoV-2 B.1.1.7 variant has seventeen mutations in the viral genome with eight mutations located in the spike, or S, protein. The B.1.351 variant, first detected in South Africa, has ten mutations located in the spike S protein. Both variants have spread at a rapid rate and are associated with increased transmission and a higher viral burden after infection. The in vitro study assessed the ability of mRNA-1273 to elicit potently neutralizing antibodies against the new SARS-CoV-2 variants, using sera from eight Phase 1 clinical trial participants who received two 100 microgram doses of mRNA-1273, and separately using sera from non-human primates, or NHPs, immunized with two doses of 30 microgram or 100 microgram of mRNA-1273. For the B.1.1.7 variant, neutralizing antibody titers remained high and were generally consistent with neutralizing titers relative to prior variants. No significant impact on neutralization was observed from either the full set of mutations found in the B.1.1.7 variant or from specific key mutations of concern. Although these mutations have been reported to lessen neutralization from convalescent sera and to increase infectivity, sera from the Phase 1 participants and NHPs immunized with mRNA-1273 were able to neutralize the B.1.1.7 variant to the same level as prior variants. For the B.1.351 variant, vaccination with the Moderna COVID-19 Vaccine produces neutralizing antibody titers that remain above the neutralizing titers that were shown to protect NHPs against wildtype viral challenge. While thecCompany expects these levels of neutralizing antibodies to be protective, pseudovirus neutralizing antibody titers were approximately 6-fold lower relative to prior variants. These lower titers may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains.

ShowHide Related Items >><<
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/06/21 Piper Sandler
Moderna price target raised to $170 after EU vaccine approval at Piper Sandler
01/04/21 Piper Sandler
Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

MRNA Moderna
$131.01 /

-1.97 (-1.48%)

Recommendations
Baird ups Tesla target, says Musk may want 'superstructure' of businesses » 08:16
01/25/21
01/25
08:16
01/25/21
08:16
TSLA

Tesla

$846.69 /

+1.86 (+0.22%)

Baird analyst Ben Kallo…

Baird analyst Ben Kallo raised the firm's price target on Tesla to $728 from $488 and reiterates an Outperform rating on the shares ahead of the company's Q4 results on Wednesday. The stock in premarket trading is up 1% to $856.00. After breaking ground on factories in Berlin and Austin, launching Shanghai operations in earnest and keeping promises of selling 500,000 cars in 2020, Tesla is entering the next stage of its evolution, Kallo tells investors in a research note. CEO Elon Musk "may be interested in proposing to combine his business interests into one superstructure," speculates the analyst. Kallo believes bias for the stock remains to the upside in the near term.

ShowHide Related Items >><<
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

01/22/21 JPMorgan
JPMorgan boosts target on 'lofty' valued Tesla to $125 from $105
01/22/21 Nomura
Nomura starts 'Tesla-like' NIO with Buy rating, $80.30 price target
01/20/21 JPMorgan
JPMorgan boosts GM target to $63, calls 'significant contender' in autonomous
01/20/21 Deutsche Bank
Tesla price target raised to $890 from $705 at Deutsche Bank
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

  • 14
    Feb
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

Periodicals
Tesla accuses engineer of stealing trade secrets, Business Insider reports » 06:24
01/25/21
01/25
06:24
01/25/21
06:24
TSLA

Tesla

$846.69 /

+1.86 (+0.22%)

Tesla on Friday filed a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

01/22/21 JPMorgan
JPMorgan boosts target on 'lofty' valued Tesla to $125 from $105
01/22/21 Nomura
Nomura starts 'Tesla-like' NIO with Buy rating, $80.30 price target
01/20/21 JPMorgan
JPMorgan boosts GM target to $63, calls 'significant contender' in autonomous
01/20/21 Deutsche Bank
Tesla price target raised to $890 from $705 at Deutsche Bank
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

  • 14
    Feb
TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

TSLA Tesla
$846.69 /

+1.86 (+0.22%)

Hot Stocks
Dada Nexus works with retailers to provide delivery service in Shijiazhuang » 05:42
01/25/21
01/25
05:42
01/25/21
05:42
DADA

Dada Nexus

$44.93 /

+1.96 (+4.56%)

Dada Group announced it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DADA Dada Nexus
$44.93 /

+1.96 (+4.56%)

DADA Dada Nexus
$44.93 /

+1.96 (+4.56%)

01/18/21 CICC
Dada Nexus initiated with an Outperform at CICC
01/07/21 KeyBanc
Dada Nexus initiated with an Overweight at KeyBanc
12/08/20
Fly Intel: Top five analyst downgrades
12/08/20 Morgan Stanley
Dada Nexus downgraded to Equal Weight on competition risk at Morgan Stanley
DADA Dada Nexus
$44.93 /

+1.96 (+4.56%)

  • 03
    Dec
  • 05
    Jun
DADA Dada Nexus
$44.93 /

+1.96 (+4.56%)

DADA Dada Nexus
$44.93 /

+1.96 (+4.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.